Zobrazeno 1 - 10
of 27
pro vyhledávání: '"D'Annunzio, M"'
The widespread use has made preservatives become a special monitored group in commercial cosmetics, especially in the leave-on products due to the prolonged exposure. Additionally, recently there has been an increase in the demand for preservative-fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::6ade39a5341849f69b88db9f3b2fd4dd
http://hdl.handle.net/11585/525104
http://hdl.handle.net/11585/525104
Autor:
Rusconi, S., Colella, F., Adorni, F., Vitiello, P., Foca, E., Capetti, A., Meraviglia, P., Abeli, C., Bonora, S., D'Annunzio, M., Di Biagio, A., Di pietro, M., Butini, L., Orofino, G., Farina, S., D'Ettorre, G., Francisci, Daniela, Soria, A., Parruti, G., Buonomini, A. R., Tommasi, C., Trotta, M. P., Merlini, E., Marchetti, G.
Publikováno v:
Infection 39 (2011): S18–S18.
info:cnr-pdr/source/autori:Rusconi, S.; Colella, E.; Adorni, F.; Vitiello, P.; Foca, E.; Capetti, A.; Meraviglia, P.; Abeli, C.; Bonora, S.; D'Annunzio, M.; Di Biagio, A.; Di Pietro, M.; Butini, L.; Orofino, G.; Farina, S.; D'Ettorre, G.; Francisci, D.; Soria, A.; Parruti, G.; Buonomini, A. R.; Tommasi, C.; Trotta, M. P.; Merlini, E.; Marchetti, G./titolo:IMMUNOLOGICAL EFFICACY OF MARAVIROC (MVC) AS INTENSIFICATION STRATEGY IN HIV-INFECTED PATIENTS (PTS) FAILING CD4 RECOVERY ON VIROLOGICALLY-SUPPRESSIVE HAART/doi:/rivista:Infection/anno:2011/pagina_da:S18/pagina_a:S18/intervallo_pagine:S18–S18/volume:39
info:cnr-pdr/source/autori:Rusconi, S.; Colella, E.; Adorni, F.; Vitiello, P.; Foca, E.; Capetti, A.; Meraviglia, P.; Abeli, C.; Bonora, S.; D'Annunzio, M.; Di Biagio, A.; Di Pietro, M.; Butini, L.; Orofino, G.; Farina, S.; D'Ettorre, G.; Francisci, D.; Soria, A.; Parruti, G.; Buonomini, A. R.; Tommasi, C.; Trotta, M. P.; Merlini, E.; Marchetti, G./titolo:IMMUNOLOGICAL EFFICACY OF MARAVIROC (MVC) AS INTENSIFICATION STRATEGY IN HIV-INFECTED PATIENTS (PTS) FAILING CD4 RECOVERY ON VIROLOGICALLY-SUPPRESSIVE HAART/doi:/rivista:Infection/anno:2011/pagina_da:S18/pagina_a:S18/intervallo_pagine:S18–S18/volume:39
Background: HIV-infected pts failing immune recovery on virologically- suppressive HAART maintain a highly activated/ differentiated peripheral CD4 pool. We hypothesized that MVC, by specifically targeting terminally-differentiated CCR5+CD4, might pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4fbaea9f79a4b2acde3bb22f538ba8ee
https://publications.cnr.it/doc/348475
https://publications.cnr.it/doc/348475
Autor:
Rusconi, S., Vitiello, P., Adorni, F., Ferramosca, S., Foca, E., Capetti, A., Meraviglia, P., Quirino, T., Bonora, S., D Annunzio, M., Antonio Di Biagio, Di Pietro, M., Butini, L., Orofino, G., Colafigli, M., Vullo, V., Francisci, D., Andreoni, M., Merlini, E., Marchetti, G.
Publikováno v:
Infection 38 (2010): 13–13.
info:cnr-pdr/source/autori:Rusconi, S.; Vitiello, P.; Adorni, F.; Ferramosca, S.; Foca, E.; Capetti, A.; Meraviglia, P.; Quirino, T.; Bonora, S.; D'Annunzio, M.; Di Biagio, A.; Di Pietro, M.; Butini, L.; Orofino, G.; Colafigli, M.; Vullo, V.; Francisci, D.; Andreoni, M.; Merlini, E.; Marchetti, G./titolo:Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART/doi:/rivista:Infection/anno:2010/pagina_da:13/pagina_a:13/intervallo_pagine:13–13/volume:38
Publons
info:cnr-pdr/source/autori:Rusconi, S.; Vitiello, P.; Adorni, F.; Ferramosca, S.; Foca, E.; Capetti, A.; Meraviglia, P.; Quirino, T.; Bonora, S.; D'Annunzio, M.; Di Biagio, A.; Di Pietro, M.; Butini, L.; Orofino, G.; Colafigli, M.; Vullo, V.; Francisci, D.; Andreoni, M.; Merlini, E.; Marchetti, G./titolo:Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART/doi:/rivista:Infection/anno:2010/pagina_da:13/pagina_a:13/intervallo_pagine:13–13/volume:38
Publons
Background: Under HAART, 7-39% of HIV-infected patients (pts) fail to exhibit a recovery in CD4 cells despite full suppression of viral replication. In MOTIVATE trials, MVC was superior to OBT in increasing CD4 cells in ARV-experienced pts. This stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1cab8bc08ac7f4094b5f08a4ea43fafd
https://publications.cnr.it/doc/353230
https://publications.cnr.it/doc/353230
Autor:
Rusconi, S., Vitiello, P., Adorni, F., Fieramosca, S., Focà, E., D'Annunzio, M., Di Biagio, A., Di Pietro, M., Butini, L., Orofino, G., Colafigli, M., Vullo, V., Francisci, Daniela, Andreoni, M., Merlini, E., Marchetti for the HSL/MVC01/2008 Study Group, G.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3982::3957d2e85ebfd5129681593be5c8399a
http://hdl.handle.net/11391/924099
http://hdl.handle.net/11391/924099
Autor:
Hasson, H., Galli, L., Gallotta, G., Neri, V., Blanc, P., D Annunzio, M., Morsica, G., Sollima, S., Marco Merli, Lazzarin, A., Uberti-Foppa, C.
Publikováno v:
Europe PubMed Central
Scopus-Elsevier
Scopus-Elsevier
The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week toxicity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::74c6fadd9c8a30def07ea7fa69cf1b24
http://europepmc.org/abstract/med/23109014
http://europepmc.org/abstract/med/23109014